DOW JONES21,636.78-915.39 -4.06%
S&P 5002,541.47-88.60 -3.37%
NASDAQ7,502.38-295.16 -3.79%

Oppenheimer Maintains Outperform on Fate Therapeutics, Raises Price Target to $36

Oppenheimer maintains Fate Therapeutics (NASDAQ:FATE) with a Outperform and raises the price target from $27 to $36.

Benzinga · 03/03/2020 13:53

Oppenheimer maintains Fate Therapeutics (NASDAQ:FATE) with a Outperform and raises the price target from $27 to $36.